Author’s Reply by Jürgen Frevert
The purpose of Dr Frevert’s article was to
compare the neurotoxin content of each of the
BoNT-A products in the vial.[1] A new figure has
now appeared for Xeomin, 0.44 ng per vial, as
compared to the 0.6 ng previously published.[16]
This finding is somewhat dismissed as a technical
issue but, in reality, represents a 27% reduction.
Could this be due to changes in the product since
the data were first reported or the product first
used (perhaps changes in batches of active com-
ponent, for example, see Quarta[17] or other issues)?
Whatever the cause, this significant difference is
a product inconsistency that warranted further
comment, representing an important aspect of the
work to the clinicians – consistent product gives
consistent clinical results.
Data comparing the characteristics of the vari-
ous BoNT-A products andmisleadingly comparing
these to labeled units are not helping clinicians se-
lect products for use. Instead, detailed overall data,
notably on history of product consistency, such as
those previously published for Dysport,[10] are
important for clinicians and these are still awaited
for the other BoNT-A products. Perhaps the time
has also come to stop discussing BoNT-A complex
‘sizes’ in a clinical context unless and until data are
produced that clearly demonstrate any relevance to
clinical use? None now seem likely.
Andy Pickett
Toxin Science Limited, Wrexham, UK
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Author’s Reply
The main focus of the letter to the editor by
Dr Pickett[1] is the interchangeability of botulinum
toxin A dosages between products, and therefore
this answer will address this issue.
In contrast to the argument of Dr Pickett, it is
justified to draw conclusions on botulinum toxin
A products based on the potency. It is true that
the units of each product are determined by dif-
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ferent LD50 (median dose that is lethal to 50%
of animals tested) assays. However, it had been
shown that the potency assay carried out byMerz
resulted in the same number of units for
Botox/Vistabel as for Xeomin/Bocouture.
More importantly, it was demonstrated in several
clinical studies for neurologic indication[2,3] as
well as in the aesthetic field[4,5] that Botox/
Vistabel and Xeomin/Bocouture are equi-
potent. This fact is acknowledged in the summary
of product characteristics of Bocouture.[6] It is
therefore justified to calculate a specific neuro-
toxin potency based on the potency in each vial,
clearly demonstrating that Xeomin/Bocouture
requires the lowest amount of clostridial protein
to achieve the same therapeutic effect. The re-
ported reduced value for the protein content in
the Xeomin/Bocouture vial has been explained
in the article[7] and is attributed to the increased
sensitivity and precision of the ELISA method
used compared with older methods used in the
past.
Ju¨rgen Frevert
Merz Pharmaceuticals GmbH, Frankfurt, Germany
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